SCHEMBL4711209

SCHEMBL4711209

O=S(=O)(c1ccc(Cl)cc1)c1cnc2ccc(Cl)cc2c1N1CCOCC1

nearest known ligand 0.73

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 8/20 0.73
THRB P10828 1/20 0.63
HTR1A P08908 1/20 0.60
HTR2A P28223 1/20 0.60
HTR7 P34969 1/20 0.60
HTR6 P50406 1/20 0.60
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
TP53 P04637 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
ALDH1A1 P00352 4/20 0.52
HPGD P15428 1/20 0.51
LMNA P02545 4/20 0.50
HTT P42858 2/20 0.50
HSP90AA1 P07900 1/20 0.50
MAPT P10636 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
CES2 O00748 1/20 0.48
KDM4E B2RXH2 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13677076 0.94 GRM5 (0.68) GRM5THRBHTR1AHTR2AHTR7
SCHEMBL13677075 0.93 THRB (0.73) GRM5THRBHTR1AHTR2AHTR7
SCHEMBL13677078 0.92 GRM5 (0.62) GRM5THRBHTR1AHTR2AHTR7
SCHEMBL8239234 0.91 GRM5 (0.65) GRM5THRBHTR1AHTR2AHTR7
SCHEMBL8239063 0.91 GRM5 (0.62) GRM5THRBHTR1AHTR2AHTR7
SCHEMBL13677081 0.91 GRM5 (0.75) GRM5THRBHTR1AHTR2AHTR7
SCHEMBL13677105 0.91 GRM5 (0.61) GRM5THRBHTR1AHTR2AHTR7
SCHEMBL13677080 0.90 THRB (0.63) GRM5THRBHTR1AHTR2AHTR7
SCHEMBL13676935 0.90 GRM5 (0.76) GRM5THRBHTR1AHTR2AHTR7
SCHEMBL13677083 0.90 GRM5 (0.67) GRM5THRBHTR1AHTR2AHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1962849-A1 QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS Richter Gedeon NYRT (HU) 2008-09-03 EP claimed
WO-2007072093-A1 QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS RICHTER GEDEON NYRT. (HU) 2007-06-28 WO claimed
US-20090270371-A1 QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS RICHTER GEDEON NYRT. (HU) 2009-10-29 US disclosed
US-20090270371-A1 QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS RICHTER GEDEON NYRT. (HU) 2009-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270371-A1 QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS GRM5, GRIK5, GRM1 GRM5 1/4885THRB 670/4885HTR1A 63/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.